Answers are grounded in this paper and cite their sources.
1.1.Introduction:India has a low to moderate prevalence of Hepatitis C Virus (HCV) infection (0.09%-2.02%). However, in a recent population based study from Punjab, the HCV prevalence rate of 5.2% was found. The biggest milestone was achieved in March 2015, when Sofosbuvir (SOF) rolled in the Indian market. In this article, we present the results of triple therapy (Peg-Interferon (PEG-INF) + Sofosbuvir (SOF) + Ribavirin (RBV) among treatment naive Chronic Hepatitis C patients. 1.2.Material and Methods: Medical records of all the patients who were diagnosed to be treatment naïve chronic hepatitis C (HCV) and who received Triple Therapy treatment (Peg INF α2a/α2b+ Ribavirin (RBV)+ Sofosbuvir (SOF) between March 2015 and Aug 2015 were analyzed. Detailed history, physical examination and laboratory investigations were done at regular interval. HCV-RNA was repeated at 4th, 8th, 12th week and 12 weeks after the end of therapy. Sustained virological response at 12 weeks (SVR-12) was noted for all patients, in whom it was available. 1.3.Results: A total of 84 patients were included in the study. Male patients dominated in the study group [61 male (72.6%) & 23 females (27.3%)]. 38 Patients (45.2%) belonged to <40 yrs age group while 46 (54.7%) patients were >40 yrs of age. Genotype 3 was the most common genotype detected in our patients [59 (70.2%)] followed by genotype 1 [20 (23.8%)] and genotype 4 patient [5 (5.9%)]. HCV RNA was undetected at 4th week in 78 (92.85%) while End of therapy response (ETVR) was seen in 80 (95.23%) patients. Sustained virological response (SVR) at 12th week was seen in 73 (86.90 %) patients, 6 patients were lost to follow-up (LFU) while 5 did not achieve SVR. None of the patients had significant adverse effects requiring termination of therapy. History of IV drug abuse indicating this as the likely source of HCV was obtained in 15 patients (17.8%). History of HCV in one or more family member (first degree relative) was present in 10 patients (11.9%). Conclusion: With the introduction of sofosbuvir (SOF), a pan genomic directly acting antiviral (DAA) drug, in the treatment (triple therapy) protocol, not only the duration of therapy and side effects has decreased but even SVR has shown a rise. With the advent of equally/more effective interferon free regimens, treatment among chronic hepatitis C patients is bound to see a revolution.
No takes yet. Share an insight, caveat, or question.
Nirmaljeet Singh Malhi (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: